Virginie Westeel
Distinguished in Small Cell Lung Cancer (SCLC)

Virginie Westeel

Besancon, FR 
Distinguished in Small Cell Lung Cancer (SCLC)
Besancon, FR 
OverviewLocationsClinical Research

Overview

Virginie Westeel practices in Besancon, France. Westeel is rated as a Distinguished expert by MediFind in the treatment of Small Cell Lung Cancer (SCLC). Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, and Small Cell Lung Cancer (SCLC).

Their clinical research consists of co-authoring 135 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 13 articles in the study of Small Cell Lung Cancer (SCLC).

Locations

Besancon, France
Other Locations
Toulon, France
10 Rue De La Grange Batelière, Paris, 75009, France
Angers, France
Bourgogne, France
CHU Tours
Tours, France
Saint-jean-saint-germain, France
Toulouse, France
Rennes, France
Rouen, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients with EGFR-mutated Non-small Cell Lung Cancer (NSCLC) with Brain or Leptomeningeal Metastases
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 2
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drugs: AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, Vandetanib, Standard Maintenance, Pemetrexed, Durvalumab, Savolitinib, Olaparib
Study Phase: Phase 2
Study of Anti-telomerase T CD4 Immunity in Metastatic Lung Cancer
Study of Anti-telomerase T CD4 Immunity in Metastatic Lung Cancer
Enrollment Status: Completed
Publish Date: September 18, 2023
Intervention Type: Other
Study Phase: Not Applicable
View 4 Less Clinical Trials

135 Total Publications

Detecting Airway Involvement in Non-Asthmatic Eosinophilic Disorders: Diagnostic Utility of Fractional Exhaled Nitric Oxide (FeNO).
Detecting Airway Involvement in Non-Asthmatic Eosinophilic Disorders: Diagnostic Utility of Fractional Exhaled Nitric Oxide (FeNO).
Journal: Advances in respiratory medicine
Published: August 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Westeel's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile